ESM accompanying the original article “Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial” by Tonneijck L et al

ESM Fig. 2 Estimated $P_{GLO}$ (A) $R_A$ (B) and $R_E$ (C) in response to intravenous GLP-1RA exenatide administration in overweight patients with type 2 diabetes